Table 2 Anti-trastuzumab Ab levels developed in 46 patien’s serum samples and determined at a single point during trastuzumab treatment course
From: Trastuzumab immunogenicity development in patients’ sera and in laboratory animals
Administered doses before blood sample withdrawal | Sample Code | Titer | *Percentage of positive samples | |
|---|---|---|---|---|
Value | ±SD | |||
1 | T1–19 | ND | 33.33% | |
T1–20 | 4.61 | 0.62 | ||
T1–21 | 0.49 | 0.04 | ||
T1–22 | ND | |||
T1–23 | 3.64 | 0.02 | ||
T1–24 | ND | |||
2 | T1–25 | 0.73 | 0.04 | 66.67% |
T1–26 | 2.86 | 0.04 | ||
T1–27 | 6.65 | 1.78 | ||
3 | T1–28 | ND | 75% | |
T1–29 | 1.27 | 0.02 | ||
T1–30 | 2.52 | 0.05 | ||
T1–31 | 5.31 | 0.07 | ||
4 | T1–32 | 0.89 | 0.04 | 50% |
T1–33 | ND | |||
T1–34 | 7.78 | 0.24 | ||
T1–35 | 8.18 | 0.60 | ||
5 | T1–36 | 0.56 | 0.03 | NVC |
6 | T1–37 | ND | ||
7 | T1–38 | ND | ||
T1–39 | 1.07 | 0.07 | ||
8 | T1–40 | ND | 33.33% | |
T1–41 | ND | |||
T1–42 | ND | |||
T1–43 | 2.03 | 0.1 | ||
T1–44 | 2.77 | 0.44 | ||
T1–45 | ND | |||
10 | T1–46 | ND | 25% | |
T1–47 | ND | |||
T1–48 | ND | |||
T1–49 | 2.9 | 0.001 | ||
12 | T1–50 | ND | NVC | |
T1–51 | ND | |||
13 | T1–52 | ND | ||
T1–53 | ND | |||
14 | T1–54 | 3.36 | 0.06 | 16.67% |
T1–55 | ND | |||
T1–56 | ND | |||
T1–57 | 0.98 | 0.08 | ||
T1–58 | ND | |||
T1–59 | ND | |||
15 | T1–60 | 2.14 | 0.07 | NVC |
T1–61 | 0.99 | 0.03 | ||
16 | T1–62 | ND | ||
T1–63 | ND | |||
17 | T1–64 | 5.77 | 0.27 | |